Recently, cancer immunotherapy is noticed as a new therapy of cancer, in addition to surgery, chemotherapy, and radiotherapy. We have been focused on alpha-galactosylceramide (αGalCer) loaded cell treatment, that can activate invariant NKT cell, and consequently activate both innate and acquired immunity by intravenous injection. Especially, we focus on allogeneic dendritic cells pulsed with αGalCer (DCG ) treatment because of its therapeutic efficacy. Our research clarified allogeneic DCG treatment prolonged survival similar to syngeneic DCG treatment. And also we revealed allogeneic DCG treatment induced similar antitumor effect regarding NK and NKT cell activity compared to syngeneic DCG treatment. As a result, our data shows allogeneic DCG treatment could be substituted for syngeneic DCG treatment. Furthermore, our results also show that the therapeutic value of allogeneic DCG is significantly better than syngeneic DCG in a kind of tumor cell lines. According to an examination of cytotoxic activity after treatment, this superiority would be caused by enhancement of antitumor effect with acquired immunity. We are currently working on creating therapeutic models by adopting antigen-specific T cells, and examine this enhancement.
